AstraZeneca says ARISE phase III trial unsuccessful, co evaluating data UPDATE |
|
|
|
Published
:
Mon, 19 Mar 2007 12:03
|
(Adds details)LONDON (AFX) - AstraZeneca PLC said first results from a phase III clinical outcomes trial which studied AGI-1067, an investigational anti-atherosclerotic agent, show the trial did not meet its primary endpoint, and it will decide whether to continue collaborating with AtheroGenics Inc on the agent after a full analysis.The company said it was informed by AtheroGenics of the outcome of the ARISE -- Aggressive Reduction of Inflammation Stops Events -- phase III trial which studied the agent with antioxidant and anti-inflammatory effects, in patients with coronary artery disease (CAD).It failed to meet the endpoint of a statistically significant relative risk reduction in a composite cardiovascular endpoint of CV death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, use of coronary revascularisation and for angina pectoris with objective evidence of ischemia.AstreZeneca said the companies will now analyse the full data set for AGI-1067, including these first results, and after completion of the final analysis, under the terms of the licence and collaboration agreement AstraZeneca has a 45-day period in which to decide whether or not to continue with the collaboration.newsdesk@afxnews.comlamCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
Print this Story
Bayer says Nexavar shown to extend survival for liver cancer patients 